Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Tristel ( (GB:TSTL) ) has shared an update.
Tristel plc announced record performance in the first half of the fiscal year and is on track to meet or exceed its revenue growth targets. The company has made significant strides in the US market, despite slower than expected sales growth for Tristel ULT, due to complex healthcare account acquisition processes. Tristel’s technology has been included in the revised American National Standard for disinfection, reinforcing its market position. The company is also progressing with FDA clearance for its ophthalmic disinfectant and sees strong growth potential in Germany, where updated guidelines support its technology.
More about Tristel
Tristel plc is a global infection prevention company specializing in manufacturing and supplying products that use proprietary chlorine dioxide chemistry. The company is a market leader in manual decontamination of medical devices and offers sustainable sporicidal surface disinfection products. Operating from its headquarters in Snailwell, near Cambridge, Tristel serves hospitals worldwide, employing approximately 270 people across 16 subsidiaries and selling into over 40 countries. The company aims for annual revenue growth of 10% to 15% and maintains a strong financial position with no debt.
YTD Price Performance: -12.60%
Average Trading Volume: 90,520
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £186M
See more data about TSTL stock on TipRanks’ Stock Analysis page.
